[go: up one dir, main page]

BR0108610A - Compostos azapolicìclicos condensados com arila - Google Patents

Compostos azapolicìclicos condensados com arila

Info

Publication number
BR0108610A
BR0108610A BR0108610-3A BR0108610A BR0108610A BR 0108610 A BR0108610 A BR 0108610A BR 0108610 A BR0108610 A BR 0108610A BR 0108610 A BR0108610 A BR 0108610A
Authority
BR
Brazil
Prior art keywords
compounds
aryl
compounds condensed
azapolycyclic compounds
condensed
Prior art date
Application number
BR0108610-3A
Other languages
English (en)
Inventor
Paige Roanne Palmer Brooks
Jotham Wadsworth Coe
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of BR0108610A publication Critical patent/BR0108610A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/22—Bridged ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/22—Bridged ring systems
    • C07D221/24—Camphidines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Toxicology (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

"COMPOSTOS AZAPOLICìCLICOS CONDENSADOS COM ARILA". Esta invenção refere-se a compostos de Fórmula (I) e seus sais farmaceuticamente aceitáveis, em que R^1^, R^2^, e R^3^ são como definidos aqui; intermediários para a síntese de tais compostos, composições farmacêuticas contendo tais compostos; e métodos de usar tais compostos no tratamento de distúrbios neurológicos e fisiológicos.
BR0108610-3A 2000-02-25 2001-02-08 Compostos azapolicìclicos condensados com arila BR0108610A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/514,002 US6605610B1 (en) 1997-12-31 2000-02-25 Aryl fused azapolycyclic compounds
PCT/IB2001/000153 WO2001062736A1 (en) 2000-02-25 2001-02-08 Aryl fused azapolycyclic compounds

Publications (1)

Publication Number Publication Date
BR0108610A true BR0108610A (pt) 2002-11-19

Family

ID=24045406

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0108610-3A BR0108610A (pt) 2000-02-25 2001-02-08 Compostos azapolicìclicos condensados com arila

Country Status (40)

Country Link
US (3) US6605610B1 (pt)
EP (2) EP1619192B1 (pt)
JP (1) JP2003524002A (pt)
KR (1) KR100537976B1 (pt)
CN (1) CN1263745C (pt)
AP (1) AP1860A (pt)
AT (2) ATE328872T1 (pt)
AU (2) AU784081B2 (pt)
BG (1) BG65891B1 (pt)
BR (1) BR0108610A (pt)
CA (1) CA2401229C (pt)
CR (1) CR6726A (pt)
CU (1) CU23148A3 (pt)
CY (1) CY1105301T1 (pt)
CZ (1) CZ303203B6 (pt)
DE (2) DE60120366T2 (pt)
DK (2) DK1259489T3 (pt)
DZ (1) DZ3328A1 (pt)
EA (1) EA005316B1 (pt)
EE (1) EE200200475A (pt)
ES (2) ES2263640T3 (pt)
GE (1) GEP20053454B (pt)
HK (1) HK1050894A1 (pt)
HR (1) HRP20020700A2 (pt)
HU (1) HU229482B1 (pt)
IL (2) IL150639A0 (pt)
IS (1) IS2293B (pt)
MA (1) MA26875A1 (pt)
MX (1) MXPA02008311A (pt)
NO (1) NO323608B1 (pt)
NZ (1) NZ519973A (pt)
OA (1) OA12181A (pt)
PL (1) PL365163A1 (pt)
PT (1) PT1259489E (pt)
RS (1) RS51123B (pt)
SI (1) SI1259489T1 (pt)
SK (1) SK12042002A3 (pt)
UA (1) UA74813C2 (pt)
WO (1) WO2001062736A1 (pt)
ZA (1) ZA200206768B (pt)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG102686A1 (en) * 1997-12-31 2004-03-26 Pfizer Prod Inc Aryl fused azapolycyclic compounds
DK1383733T3 (da) * 2001-04-20 2008-06-09 Pfizer Prod Inc Fremgangsmåde til fremstilling af 1,3-substituerede indener og aryl-sammenföjede azapolycykliske forbindelser
MXPA04002539A (es) * 2001-10-31 2004-05-31 Pfizer Prod Inc Combatientes de los receptores de la acetilcolina nicotinica en el tratamiento del sindrome de pierna inquietas.
WO2003045967A1 (en) * 2001-11-30 2003-06-05 Pfizer Products Inc. Aryl fused azapolycyclic compounds
MXPA04003807A (es) * 2001-11-30 2004-07-30 Pfizer Prod Inc Formulaciones farmaceuticas de 5, 7, 14-trianzatetraciclo [10.3.1.02, 11, 04, 9]-hexadeca -2 (11), 3, 5, 7, 9-pentaeno.
RU2326693C2 (ru) 2002-07-18 2008-06-20 Цитос Байотекнолоджи Аг Конъюгаты гаптен-носитель и их применение
WO2004037850A2 (en) * 2002-10-22 2004-05-06 Millipore Corporation Multi-sided immersion formation of composite structures and method
PL377292A1 (pl) * 2002-11-25 2006-01-23 Pfizer Products Inc. Ulepszony sposób wytwarzania 1,3-podstawionych indenów
AU2004203983A1 (en) * 2003-01-15 2004-07-29 Pfizer Products Inc. Process for the preparation of aryl fused polycyclic lactams
EP1633358A1 (en) * 2003-05-20 2006-03-15 Pfizer Products Inc. Pharmaceutical compositions of varenicline
DK1638971T3 (da) * 2003-06-04 2008-10-27 Pfizer Prod Inc Fremstilling af substitueret Quinoxaliner fra dianilinen med 2,3-dihydroxy-1,4-dioxan
BRPI0412880A (pt) * 2003-07-21 2006-10-03 Pfizer Prod Inc compostos azapolicìclicos fundidos a arila
US8580842B2 (en) * 2003-09-30 2013-11-12 Abbott Gmbh & Co. Kg Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
MXPA06004088A (es) 2003-10-14 2006-06-27 Xenoport Inc Forma cristalina de un analogo del acido gamma-aminobutirico.
BRPI0418092A (pt) * 2003-12-23 2007-04-17 Pfizer Prod Inc combinação terapêutica para melhora cognitiva e transtornos psicóticos
WO2006006071A1 (en) * 2004-07-07 2006-01-19 Pfizer Products Inc. Resolution of an aryl-fused azapolycyclic compound
CN101128462A (zh) * 2005-02-24 2008-02-20 辉瑞产品有限公司 高纯度取代喹喔啉的制备
MX2008013606A (es) * 2006-04-24 2008-10-30 Pfizer Prod Inc Membranas asimetricas para dispositivos de administracion de farmacos.
JP2010527907A (ja) * 2006-11-09 2010-08-19 ファイザー・プロダクツ・インク ニコチン様中間体の多形体
US20080167286A1 (en) 2006-12-12 2008-07-10 Abbott Laboratories Pharmaceutical compositions and their methods of use
US8486979B2 (en) * 2006-12-12 2013-07-16 Abbvie Inc. 1,2,4 oxadiazole compounds and methods of use thereof
UY30846A1 (es) 2006-12-30 2008-07-31 Abbott Gmbh & Amp Derivados de oxindol sustituidos, medicamentos que los comprenden y uso de los mismos
US20090062257A1 (en) * 2007-08-29 2009-03-05 Protia, Llc Deuterium-enriched varenicline
WO2009034431A2 (en) 2007-09-10 2009-03-19 Pfizer Inc. Controlled-release dosage forms for varenicline
WO2009065872A2 (en) * 2007-11-20 2009-05-28 Medichem, S.A. Improved processes for the synthesis of varenicline l-tartrate
MX2010006202A (es) * 2007-12-07 2011-03-04 Abbott Gmbh & Co Kg Derivados de oxindol substituidos por amidometil y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina.
US8703774B2 (en) 2007-12-07 2014-04-22 AbbVie Deutschland GmbH & Co. KG Carbamate-substituted oxindole derivatives and use thereof for the treatment of vasopressin-dependent diseases
ES2397125T3 (es) * 2007-12-07 2013-03-04 Abbott Gmbh & Co. Kg Derivados de oxindol sustituidos con halógeno en la posición 5 y su uso para la producción de un medicamento para el tratamiento de enfermedades dependientes de la vasopresina
US8546401B2 (en) * 2007-12-07 2013-10-01 AbbVie Deutschland GmbH & Co. KG 5,6-disubstituted oxindole-derivatives and use thereof for treating vasopressin-dependent diseases
US8383657B2 (en) 2007-12-21 2013-02-26 Abbott Laboratories Thiazolylidine urea and amide derivatives and methods of use thereof
EP2271344A4 (en) * 2008-03-31 2011-04-27 Univ South Florida METHOD FOR TREATING ILLNESS-RELATED ATAXIA AND NON-ATTACHIC IMBALANCE
US8039620B2 (en) * 2008-05-22 2011-10-18 Teva Pharmaceutical Industries Ltd. Varenicline tosylate, an intermediate in the preparation process of varenicline L-tartrate
US20090318695A1 (en) * 2008-06-19 2009-12-24 Vinod Kumar Kansal Processes for the preparation of varenicline and intermediates thereof
WO2010005643A1 (en) * 2008-07-10 2010-01-14 Teva Pharmaceutical Industries Ltd. Processes for purifying varenicline l-tartrate salt and preparing crystalline forms of varenicline l-tartrate salt
US8314235B2 (en) * 2008-09-01 2012-11-20 Actavis Group Ptc Ehf Process for preparing varenicline, varenicline intermediates, pharmaceutically acceptable salts thereof
AU2010214101A1 (en) * 2009-02-11 2011-09-01 Sunovion Pharmaceuticals Inc. Histamine H3 inverse agonists and antagonists and methods of use thereof
WO2010138600A2 (en) 2009-05-29 2010-12-02 Abbott Laboratories Pharmaceutical compositions for the treatment of pain
WO2010151524A1 (en) * 2009-06-22 2010-12-29 Teva Pharmaceutical Industries Ltd Solid states forms of varenicline salts and processes for preparation thereof
KR20180101268A (ko) 2017-03-03 2018-09-12 주식회사 씨티씨바이오 바레니클린 또는 이의 약학적으로 허용가능한 염의 포접 복합체를 포함하는 구강 투여용 제제
EP4084797A4 (en) * 2020-01-03 2024-02-21 Blue Oak Pharmaceuticals, Inc. COMPOUNDS AND COMPOSITIONS FOR TREATING CNS DISEASES
CN115322105A (zh) * 2021-05-11 2022-11-11 江苏润安制药有限公司 一种合成艾拉莫德关键中间体的方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3471503A (en) 1967-05-05 1969-10-07 Mcneilab Inc 1,2,3,5,6,7-hexahydro-4-phenethyl-2,6-methano-4h-4- benzazonin-12-ols
SG102686A1 (en) * 1997-12-31 2004-03-26 Pfizer Prod Inc Aryl fused azapolycyclic compounds
EP0955301A3 (en) 1998-04-27 2001-04-18 Pfizer Products Inc. 7-aza-bicyclo[2.2.1]-heptane derivatives, their preparation and use according to their affinity for neuronal nicotinic acetylcholine receptors
WO1999055680A1 (en) 1998-04-29 1999-11-04 Pfizer Products Inc. Aryl fused azapolycyclic compounds
HUP0200332A3 (en) * 1999-01-29 2002-09-30 Abbott Lab Diazabicyclic derivatives as nicotinic acetylcholine receptor ligands pharmaceutical compositions comprising thereof and their use
FR2788982B1 (fr) * 1999-02-02 2002-08-02 Synthelabo Compositions pharmaceutiques contenant de la nicotine et leur application dans le sevrage tabagique
IL137937A0 (en) * 1999-08-27 2001-10-31 Pfizer Prod Inc A pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal
EP1372692A4 (en) * 2001-03-19 2005-10-26 Sloan Kettering Inst Cancer ASYMMETRIC SYNTHESIS OF (S, S, R) - (-) - ACTINONE AND ITS ANALOG AND USES THEREOF
BRPI0412880A (pt) * 2003-07-21 2006-10-03 Pfizer Prod Inc compostos azapolicìclicos fundidos a arila
US8123947B2 (en) 2007-10-22 2012-02-28 Baxter International Inc. Priming and air removal systems and methods for dialysis

Also Published As

Publication number Publication date
DK1619192T3 (da) 2010-03-29
CR6726A (es) 2003-10-28
AP1860A (en) 2008-07-02
NO323608B1 (no) 2007-06-18
ATE328872T1 (de) 2006-06-15
AP2002002604A0 (en) 2002-09-30
IS6459A (is) 2002-07-05
DE60120366T2 (de) 2007-07-05
IL150639A (en) 2011-10-31
HK1050894A1 (en) 2003-07-11
SK12042002A3 (sk) 2004-02-03
EE200200475A (et) 2003-12-15
SI1259489T1 (sl) 2006-10-31
HRP20020700A2 (en) 2004-12-31
EP1619192A2 (en) 2006-01-25
ATE453643T1 (de) 2010-01-15
US7144882B2 (en) 2006-12-05
UA74813C2 (en) 2006-02-15
RS51123B (sr) 2010-10-31
AU784081B2 (en) 2006-02-02
CY1105301T1 (el) 2010-03-03
BG65891B1 (bg) 2010-04-30
CZ20022778A3 (cs) 2003-09-17
EP1259489B1 (en) 2006-06-07
NO20024042L (no) 2002-10-17
NZ519973A (en) 2004-04-30
PL365163A1 (en) 2004-12-27
AU2874801A (en) 2001-09-03
DK1259489T3 (da) 2006-10-09
KR20030005209A (ko) 2003-01-17
CA2401229C (en) 2007-10-02
ES2263640T3 (es) 2006-12-16
US7205300B2 (en) 2007-04-17
ES2336800T3 (es) 2010-04-16
AU2005234671A1 (en) 2005-12-15
EA200200716A1 (ru) 2003-02-27
OA12181A (en) 2006-05-09
CN1406227A (zh) 2003-03-26
EA005316B1 (ru) 2004-12-30
YU59602A (sh) 2005-06-10
DZ3328A1 (pt) 2001-08-30
US6605610B1 (en) 2003-08-12
MXPA02008311A (es) 2002-12-09
CN1263745C (zh) 2006-07-12
DE60140965D1 (de) 2010-02-11
MA26875A1 (fr) 2004-12-20
CZ303203B6 (cs) 2012-05-23
BG106908A (bg) 2003-04-30
GEP20053454B (en) 2005-02-25
DE60120366D1 (de) 2006-07-20
US20030130260A1 (en) 2003-07-10
PT1259489E (pt) 2006-08-31
ZA200206768B (en) 2003-09-23
NO20024042D0 (no) 2002-08-23
AU2005234671B2 (en) 2008-04-17
CU23148A3 (es) 2006-06-29
IL150639A0 (en) 2003-02-12
EP1619192B1 (en) 2009-12-30
EP1619192A3 (en) 2006-03-22
IS2293B (is) 2007-10-15
JP2003524002A (ja) 2003-08-12
EP1259489A1 (en) 2002-11-27
WO2001062736A1 (en) 2001-08-30
KR100537976B1 (ko) 2005-12-21
HUP0204580A3 (en) 2005-04-28
US20030130261A1 (en) 2003-07-10
CA2401229A1 (en) 2001-08-30
HUP0204580A2 (hu) 2003-04-28
HU229482B1 (en) 2014-01-28

Similar Documents

Publication Publication Date Title
BR0108610A (pt) Compostos azapolicìclicos condensados com arila
BR9814592A (pt) "compostos azopolicìclicos condensados com arila"
BR9901491A (pt) 7-hetero-biciclo [2.2.1] - heptanos.
BRPI0001486B8 (pt) processos e intermediários para preparar compostos anticancerígenos
BR0205890A (pt) Pirazolopirimidinas como agentes terapêuticos
BR9709959A (pt) Derivados tricìclicos de fenilamino substituìdo para o tratamento de doenças hiperproliferativas
BR0215622A (pt) Inibidores da dpiv com base em glutaminila
TR200201505T2 (tr) Terapötik maddeler olarak pirazolopirimidinler
BR0205889A (pt) Pirazolopirimidinas como agentes tepapêuticos
BR0210507A (pt) Azaindóis
BR9713552A (pt) Derivados de pirimidina bicìclicos condensados
UY25679A1 (es) Derivados de quinolin-2-ona inhibidores de la farnesil proteína transferasa útiles como agentes contra el cáncer
BR0201437A (pt) Processo para preparar derivados de 9-desoxo-9a-aza-9a-homoeritromicina a 4"-substituìdos"
MY140693A (en) [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
BR0015911A (pt) Derivados de benzoimidazole úteis como agentes antiproliferativos
BRPI0418031A (pt) inibidores de quinase fosfonato-substituìdos
PT1029853E (pt) Derivados biciclicos heteroaromaticos uteis como agentes anticancerigenos
BR9807876A (pt) Compostos heterocìclicos e seu uso para inibição de peptìdeo beta-amilóide
BR0312232A (pt) Inibidores de caspases e seus usos
BRPI0411891A (pt) pirazol[3,4-b]piridin-6-onas como inibidores de gsk-3
BR9916680A (pt) Derivados da 3,3-biarilpiperidina e2,2-biarilmorfolina
BR9910058A (pt) Compostos azapolicìclicos aril-condensados
DE69917005D1 (de) Substituierte pyrrolobenzimidazolderivate zur entzündungshemmung
BRPI0412880A (pt) compostos azapolicìclicos fundidos a arila
BRPI0211025B8 (pt) um novo composto para o tratamento da impotência

Legal Events

Date Code Title Description
B15K Others concerning applications: alteration of classification

Free format text: ALTERADA DA INT.CL: C07D 221/22, C07D 471/08, C07D 498/08, C07D 513/08, A61K 31/435

Ipc: C07D 221/22 (2010.01), C07D 471/08 (2010.01), C07D

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.